Marseille, France, December 5, 2025 05:00 a.m. ET / 11:00 a.m. CET– ImCheck Therapeuticsannounced today an oral presentation at the upcoming  American Society of Hematology (ASH) Annual Meeting 2025, taking place from December 6 to December 9, in Orlando, FL, USA.  The presentation will highlight the high remission rates and overall survival observed in EVICTION, ImCheck’s open-label, randomized Phase I/II study evaluating ICT01, a first-in-class γ9δ2 T-cell activator, in combination with azacitidine and venetoclax in older or unfit patients with newly diagnosed acute myeloid leukemia (AML).

Details of the oral presentation at ASH 2025 are:

Abstract Title: “γ9δ2 T-cell (γ9δ2TC) activation with ICT01 and azacitidine-venetoclax (Aza-Ven) induces high rates of remission and overall survival in patients with newly diagnosed (ND) acute myeloid leukemia (AML): Results from the phase 1/2 study eviction”

Presenter: Sylvain GARCIAZ, MD, PhD, Institut Paoli-Calmettes, Marseille, France

Session: 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Immunotherapy and chemotherapy combinations in AML

Room: OCCC - Chapin Theater (320)

Date: Sunday, December 7, 2025

Time: 5:15 p.m.- 5:30 p.m. ET

The ASH presentation will be available on ImCheck’s corporate website after the presentation has been held.